A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes
| Status: | Terminated |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 74 |
| Updated: | 6/8/2017 |
| Start Date: | January 12, 2016 |
| End Date: | May 25, 2017 |
Comparative Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered Subcutaneously as a Bolus Via Syringe Versus Continuous Subcutaneous Insulin Infusion and Characterization of TID and BID Dosing at Steady State in High-Dose Insulin-Treated Subjects With Type 2 Diabetes Mellitus
This purpose of this two-part study is to measure how much of the study drug gets into the
blood stream and how long it takes the body to get rid of it. In Part A, each participant
will receive two treatments, a single dose and a continuous dose of U-500R insulin, both
administered just under the skin. Participants who complete Part A will continue into Part B
where they will be assigned to 1 of 2 treatments with U-500R insulin, injected either twice
or three times daily under the skin for 5-10 days. This study can last from 7-14 weeks
including initial screening and follow up.
blood stream and how long it takes the body to get rid of it. In Part A, each participant
will receive two treatments, a single dose and a continuous dose of U-500R insulin, both
administered just under the skin. Participants who complete Part A will continue into Part B
where they will be assigned to 1 of 2 treatments with U-500R insulin, injected either twice
or three times daily under the skin for 5-10 days. This study can last from 7-14 weeks
including initial screening and follow up.
Inclusion Criteria:
- Males or females with type 2 diabetes mellitus (T2DM)
- Are current users of U-100, U-200 and/or U-300 insulin/analog as, basal, premixed
and/or basal/bolus delivered with any injection device (pens and/or syringe/vial but
excluding continuous subcutaneous infusion (CSII)/insulin pump use in the preceding 3
months), taking a total daily dose (TDD) of greater than or equal to (≥) 150 units
(U) or at least one dose greater than (>) 100 U as part of a multiple daily injection
(MDI) regimen and TDD less than or equal to (≤)3.0 units per kilogram (U/kg)
- Concomitant antihyperglycemic agent(s) (AHA) therapy may include: metformin (MET),
dipeptidyl peptidase 4 inhibitors, pioglitazone (doses ≤30 milligrams per day
(mg/day)), glucagon like peptide (GLP)-1 receptor agonists, sodium-glucose
co-transporter-2 (SGLT2) inhibitors, except in combination with GLP-1 receptor
agonists
- Participant's antihyperglycemic agent (AHA) therapy must have been stable for ≥3
months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4
months)
- Have hemoglobin A1c (HbA1c) 7.5-11.5 percent (%)
Exclusion Criteria:
- Have type 1 diabetes mellitus (T1DM), or other types of diabetes mellitus apart from
T2DM
- Have known hypersensitivities or allergies to insulin, excipients contained in
insulin products, or related compounds
- Have used U-500R within 3 months prior to screening
- Have used rosiglitazone, pramlintide, once weekly or twice daily exenatide, or other
injectable or oral antihyperglycemic agent(s) not listed in the inclusion criterion;
or are taking oral antidiabetic medications at doses exceeding the respective product
labels
- Have had a blood transfusion or severe blood loss within 3 months prior to screening
or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia which may
affect reliability of HbA1c measurements
We found this trial at
1
site
Chula Vista, California 91911
Principal Investigator: L Morrow
Phone: 619-409-1268
Click here to add this to my saved trials
